Suven Life Sciences Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, to both major stock exchanges. The pharmaceutical company filed the mandatory certificate on April 06, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Filing Details

The company submitted the certificate to both BSE Limited and National Stock Exchange of India Limited, fulfilling its obligations under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018. The filing was signed by K Sangeetha Laxmi, Company Secretary, on behalf of Suven Life Sciences Limited.

Registrar Confirmation

Kfin Technologies Limited, serving as the Registrar and Share Transfer Agent for Suven Life Sciences Limited, issued certificates dated April 01, 2026. The certificates were addressed to both Central Depository Services (India) Limited and National Securities Depository Limited, confirming compliance with regulatory requirements.

C Shobha Anand, Vice President at Kfin Technologies Limited, signed the certificates confirming that:

• Details of securities dematerialized and rematerialized during the quarter have been properly documented
• All required information has been furnished to stock exchanges where the company's shares are listed
• The company has met its obligations under SEBI regulations

Corporate Information

Suven Life Sciences Limited operates from its registered office located at 8-2-334 I SDE Serene Chambers, 6th Floor Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500 034, Telangana. The company maintains investor communication through its dedicated email and website channels.

Compliance Significance

This quarterly filing represents a standard regulatory requirement under SEBI's framework for depositories and participants. The certificate ensures transparency in the dematerialization and rematerialization process of securities, providing stakeholders with confidence in the proper handling of share transactions during the quarter ended March 31, 2026.

Suven Life Sciences Limited's Board of Directors has formally approved the conversion of warrants into equity shares, completing a significant capital raising exercise. The board meeting held on March 6, 2026, resulted in the allotment of 3,17,68,764 equity shares to a promoter group entity, strengthening the company's financial position.

Board Meeting Outcome

The Board of Directors meeting, which commenced at 11:00 AM IST and concluded at 11:20 AM IST on March 6, 2026, approved the conversion of fully paid warrants into equity shares. The conversion was executed in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Allotment Details

The company has allotted 3,17,68,764 equity shares of ₹1 each to JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole trustee of Jasti Family Trust. This promoter group entity has provided 100% consideration amount aggregating to ₹425,70,14,376 in compliance with regulatory requirements.

Capital Structure Impact

The warrant conversion has resulted in a significant expansion of the company's equity base. The paid-up equity share capital has increased substantially following the allotment.

Shareholding Pattern Changes

Following the preferential allotment, Jasti Property and Equity Holdings Private Limited's shareholding has increased significantly. The regulatory disclosure filed on March 9, 2026, reveals the updated shareholding structure of the promoter group.

Regulatory Compliance

The allotment was conducted as a preferential issue in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018. The company has fulfilled all disclosure requirements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete transparency in the process. Additionally, Jasti Property and Equity Holdings Private Limited has filed the mandatory disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirming the acquisition details to both BSE and NSE.

This successful warrant conversion demonstrates strong promoter confidence and provides Suven Life Sciences with enhanced financial resources to pursue its strategic objectives in the pharmaceutical sector.